Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Price:
1.15 USD
-1.71%
Market Closed
Updated:
May 15, 2024
Adaptimmune Therapeutics PLC
EPS (Diluted)
|
Adaptimmune Therapeutics PLC
EPS (Diluted) Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive EPS (Diluted) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
EPS (Diluted)
$0
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
EPS (Diluted)
-$1
|
CAGR 3-Years
-136%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
EPS (Diluted)
-$1
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
EPS (Diluted)
-$3
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
EPS (Diluted)
-£1
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
EPS (Diluted)
£0
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
See Also
What is Adaptimmune Therapeutics PLC's EPS (Diluted)?
EPS (Diluted)
-0.1
USD
-0.1
USD
Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's EPS (Diluted) amounts to -0.1 USD.
What is Adaptimmune Therapeutics PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
11%
11%
Over the last year, the EPS (Diluted) growth was 47%. The average annual EPS (Diluted) growth rates for Adaptimmune Therapeutics PLC have been 16% over the past three years , 11% over the past five years .
You don't have any saved screeners yet
